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Abstract
Objectives: To estimate the prevalence of epilepsy in children with Autism Spectrum Disorder (ASD) and to determine the
demographic and clinical characteristics of children with ASD and epilepsy in a large patient population.
Methods: Cross-sectional study using four samples of children with ASD for a total of 5,815 participants with ASD. The
prevalence of epilepsy was estimated from a population-based sample. Children with and without epilepsy were compared
on demographic and clinical characteristics. Multivariate logistic regression was used to examine the association between
demographic and clinical characteristics and epilepsy.
Results: The average prevalence of epilepsy in children with ASD 2–17 years was 12.5%; among children aged 13 years and
older, 26% had epilepsy. Epilepsy was associated with older age, lower cognitive ability, poorer adaptive and language
functioning, a history of developmental regression and more severe ASD symptoms. The association between epilepsy and
the majority of these characteristics appears to be driven by the lower IQ of participants with epilepsy. In a multivariate
regression model, only age and cognitive ability were independently associated with epilepsy. Children age 10 or older had
2.35 times the odds of being diagnosed with epilepsy (p,.001) and for a one standard deviation increase in IQ, the odds of
having epilepsy decreased by 47% (p,.001).
Conclusion: This is among the largest studies to date of patients with ASD and co-occurring epilepsy. Based on a
representative sample of children with ASD, the average prevalence of epilepsy is approximately 12% and reaches 26% by
adolescence. Independent associations were found between epilepsy and older age and lower cognitive ability. Other risk
factors, such as poor language and developmental regression, are not associated with epilepsy after controlling for IQ.
These findings can help guide prognosis and alert clinicians to patients with ASD who are at increased risk for epilepsy.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by deficits in social interaction and
communication and the presence of restricted and repetitive
behavior. Epilepsy is a neurologic condition characterized by
recurrent, unprovoked seizures [1]. The co-occurrence of ASD
and epilepsy is well established among clinicians and researchers
[2,3] but the characteristics of children with both conditions have
not been studied in large, contemporary datasets. Epilepsy is
commonly reported to occur in 30% of individuals with ASD
[3,4,5,6], which exceeds that of the general population (0.7–1%)
[7] but prevalence estimates have varied widely, ranging from 5%
to 46% [2,3,8,9,10,11,12,13,14,15,16,17]. This variation is likely
due to differences between prior studies in the age and cognitive
level of participants and in the sampling and diagnostic methods
used. Many previous studies of epilepsy in ASD have had small
sample sizes that are unlikely to be representative of the general
ASD population and insufficiently powered to make rigorous
conclusions about risk factors [8,18]. In addition, some prior
studies were based on previous diagnostic criteria for ASD [10,19].
Prior studies have reported that epilepsy in ASD is associated
with female gender [15,18,20,21], lower cognitive ability
[9,14,15,20,21] and adaptive functioning [21], and a history of
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developmental regression [22,23]. However, findings have been
inconsistent and often contradictory, which is likely due to small
sample sizes. At present, there is insufficient information to make
strong predictions as to which individuals with ASD are at greatest
risk for epilepsy and what the associated clinical characteristics
may be.
We conducted among the largest studies to date on the co-
occurrence of ASD and epilepsy. The aim was to compare
children with ASD and epilepsy to children with ASD alone on
demographic and clinical characteristics. Participants were drawn
from four samples; an epidemiologic population-based sample (the
2007 National Survey of Children’s Health) and three genetic
collaborative samples (the Autism Genetic Resource Exchange,
the Simons Simplex Collection, and the Autism Consortium).
Combining all samples, a total of 5,815 individuals with ASD were
studied. Using this large sample we provide important insights
regarding the prevalence and clinical correlates of epilepsy in this
subgroup of patients with ASD.
Methods
Ethics Statement
All research was approved by institutional review boards (IRB).
Parents gave informed consent to participate in each of the studies.
For the 2007 NSCH study, the NSCH IRB approved all study
procedures. Verbal informed consent for study participation was
approved by the NSCH IRB. Written consent was not obtained
because of the nature of the phone-based interview. Verbal
consent was obtained and documented in the computer-assisted
telephone interview (CATI) system. For the AGRE, SSC, and AC
studies written consent was obtained according to procedure that
was approved by the ethics committees. Research was approved
by the Lifespan Health IRB Study # 4114–09.
Subjects
Subjects were enrolled in one of the four studies described
below. See Table 1 for a summary of the study populations.
2007 National Survey of Children’s Health (NSCH)
The NSCH is a nationally representative random-digit-dial
telephone-based survey sponsored by the U.S. Department of
Health and Human Services Administration Maternal and Child
Health Bureau and conducted by the National Center for Health
Statistics of the Centers for Disease Control and Prevention. A
parent/guardian was asked questions regarding the child’s health
during a telephone interview. A sampling weight was provided by
the NSCH with the data record for each child. This weight is
based on the probability of selection of the child’s telephone
number, with adjustments for known survey response biases and
further adjustments to ensure that weighted estimates match
demographic control totals from the U.S. Census Bureau’s
American Community Survey. Weighted results represent the
population of non-institutionalized children ages 0–17 at the
national and state level. Substantive and methodological details of
the survey have been previously described [24]. Out of 81,176
children aged 2 to 17 years in the sample, there were 921 children
with a current diagnosis of ASD used in the present study.
Autism Genetic Resource Exchange (AGRE)
The AGRE is a collection of genetic and phenotypic data on
families with ASD from across the United States. The majority of
families have more than one child affected with ASD (multiplex
families) [25,26]. Detailed information on the study methodology
has been previously described [26]. The AGRE sample used in the
present study includes 2,524 individuals with ASD.
Simons Simplex Collection (SSC)
The SSC is a collection of genetic and phenotypic data on
simplex families (one child affected with ASD) across the United
States. Families were recruited from clinics serving children with
ASD and were included if the family had only one child aged 4–18
years who met criteria for ASD. Detailed information on inclusion
and exclusion criteria can be found in the SFARI Base/SSC
Researcher Welcome Packet [27] and additional information on
the study methodology has been previously described [28]. The
SSC sample used in the present study includes 1,891 children with
ASD from version 9 (released 8/2/2010).
Autism Consortium (AC)
The AC is a collection of genetic and phenotypic data on
simplex and multiplex families of individuals with ASD in the
Massachusetts area. Families were recruited from Boston area
hospitals. There were no specific inclusion or exclusion criteria.
The AC sample used in the present study includes 479 individuals
with ASD.
Table 1. Summary of Samples and Measures.
Sample
The Autism Genetic
Resource Exchange (AGRE)
The Simons Simplex
Collection (SSC)
The Autism
Consortium (AC)
The 2007 National Survey of
Children’s Health (NSCH)
Total ASD Sample Size 2,524 1,891 479 921
Description of Sample Majority multiplex families (more
than one child with ASD) in U.S.
Simplex families (only one
child with ASD) in U.S.
Simplex and multiplex
families in New England.
Population-based survey of
children in U.S.
ASD Diagnosis Standardized diagnostic
assessments
Standardized diagnostic
assessments
Standardized diagnostic
assessments
NSCH survey
Epilepsy Diagnosis ADI-R ADI-R ADI-R NSCH survey
Cognitive Ability Available Available Available Not available
Adaptive Functioning Available Available Available Not available
Language Available Available Available Not available
Developmental Regression Available Available Available Not available
ASD Severity Available Available Available Not available
Abbreviations: ASD, Autism Spectrum Disorder; ADI-R, Autism Diagnostic Interview–Revised.
doi:10.1371/journal.pone.0067797.t001
Autism Spectrum Disorder and Epilepsy
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Measures
Autism Spectrum Disorder (ASD). All of the subjects in the
study had been diagnosed, or were reported to be diagnosed, with
ASD. In the genetic collaborative samples, diagnosis of ASD was
based on standardized diagnostic assessments including the Autism
Diagnostic Interview–Revised (ADI-R) [29] and the Autism
Diagnostic Observation Schedule (ADOS) [30]. The SSC and
AC samples used in the present study included individuals meeting
criteria for a less severe diagnostic classification of ‘ASD’ on the
ADI-R (equivalent to DSM-IV PDD-NOS [31]) based on
modified cut-off scores widely used in ASD research [32]. In the
AGRE sample, only individuals who met ADI-R criteria for
autism were included because information on the ‘ASD’ classifi-
cation was not available.
In the NSCH, diagnosis of ASD was based on parent-report.
During the phone interview, parents of children aged 2–17 years
were asked if they had ever been told by a doctor or other health
care provider that their child had ‘‘autism, Asperger disorder,
pervasive developmental disorder, or other autism spectrum
disorder.’’ If parents responded affirmatively, they were then
asked if their child currently had ASD. All 2–17 year old children
reported to be currently diagnosed with ASD were included in the
present study (n= 921).
Epilepsy. Diagnosis of epilepsy was based on parent report in
all of the samples. In the genetic collaborative samples, epilepsy
was measured by parent response to an ADI-R question asking if
the child ‘‘has ever fainted or had a fit or seizure or convulsion?’’
The child was classified as having been diagnosed with epilepsy if
the parent reported that the child had a definite diagnosis of
epilepsy. The child was classified as having never been diagnosed
with epilepsy if the parent reported the child had had no attacks or
febrile convulsions only. Sixty-three children from AGRE and one
child from SSC were missing data on epilepsy and were therefore
excluded from the analyses. Children reported to have a ‘‘history
of attacks that might be epileptic, but diagnosis not established’’
were excluded from the analyses to prevent misclassification
(n = 323 participants total from AGRE, SSC, and AC). Table 2
presents demographic characteristics of the entire sample,
including these 323 participants. Tables 3–6 and Tables S1–S9
in Supporting Information S1 present analyses excluding these
participants.
In the NSCH, during the phone-based interview, parents were
asked if they had ever been told by a doctor or other health care
provider that their child had ‘‘epilepsy or seizure disorder.’’
Children reported to be currently or ever diagnosed with epilepsy
were classified as having epilepsy.
Clinical Characteristics
Clinical characteristics were available for subjects in the genetic
collaborative samples (Table 1).
Cognitive ability. Cognitive ability was measured via stan-
dardized intelligence tests, each of which provided an intelligence
quotient (IQ). IQ data were available for a subset of AGRE
participants (n = 469) who completed the Stanford Binet Intelligence
Scales, 5th Edition [33]. IQ data were available for all SSC
participants, the majority (n = 1632) of whom completed the
Differential Ability Scales, 2nd Edition (DAS-II) [34]; a minority
completed other cognitive assessments. IQ data were available for
a subset of AC participants (n = 273) derived from a variety of
intelligence tests including the Mullen Scales of Early Learning [35],
the Wechsler Abbreviated Scale of Intelligence (WASI) [36], the Wechsler
Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III)
[37], and the DAS-II. Full-scale IQ scores were used to create a
dichotomous Intellectual Disability (ID) variable defined as IQ at
or below 70 (ID) versus above 70 (not ID).
Adaptive functioning. Adaptive functioning was measured
by the Vineland Adaptive Behavior Scales, Second Edition
(Vineland-II) [38], a valid and reliable measure of adaptive
functioning. The Adaptive Behavior Composite score is a
summary score derived by adding the standard scores for each
domain (communication, daily living skills, socialization, and
motor skills). The Motor Skills standard score is derived from the
motor skills domain, which is comprised of two subdomains: gross
and fine motor skills. This score was available for subjects less than
seven years of age.
Developmental regression. A history of developmental
regression was measured by parent response to various questions
on the ADI-R. Detailed descriptions of the items can be found in
the ADI-R manual [29]. We created a composite variable for any
regression, defined as a loss of any previously acquired commu-
nication or social skill. This was based on all items from the ADI-R
pertaining to loss of language or other skills. We also examined two
specific items, ‘‘loss of any language’’ and ‘‘loss of any skills.’’
Language. Language was measured by parent report re-
sponse to an ADI-R question regarding the child’s current overall
use of language and by the Peabody Picture Vocabulary Test (PPVT)
[39], which measures receptive one-word vocabulary. PPVT data
were available for 1,277 AGRE, 1,748 SSC, and 337 AC
participants.
ASD severity. ASD severity was measured by the ADOS
Calibrated Severity score, a severity metric created by Gotham,
Pickles, and Lord [40] that takes into account age and language level
and isbasedonrawtotal scoresof theAutismDiagnosticObservation
Schedule (ADOS) [41]. The Calibrated Severity score was available
for genetic collaborative participants administered ADOS modules
1–3, as it has not been devised for module 4.
Statistical Methods
Statistical analyses were conducted using SAS software, version
9.3. Bivariate analyses were conducted to compare individuals
with and without epilepsy on demographic and clinical charac-
teristics. Chi-square and t-test p-values were calculated when
appropriate. Statistical significance was evaluated using 2-sided
tests at a 0.05 alpha-level. For the NSCH, we computed the
weighted prevalence of epilepsy in the entire sample of children
with ASD and in subgroups. Using proc survey weights in SAS,
the survey weights adjust the survey responses to reflect
characteristics of the non-institutionalized population of children
in the US. We report unweighted sample sizes, weighted
percentages, and weighted 95% confidence intervals for estimated
rates.
Logistic regression was used to examine the association between
epilepsy and demographic and clinical characteristics among
genetic collaborative study participants. We report odds ratios and
95% confidence intervals. Cases with missing values were
excluded. We fit separate models for each variable (model 1),
separate models for each variable adjusted for IQ score (model 2),
and a model with all of the predictors entered simultaneously
(model 3). Model diagnostics performed on the final multivariate
model (model 3) included the removal of outliers, checking for
normal distribution of continuous predictors, checking for over-
dispersion, and testing model fit using the Hosmer-Lemeshow
Test. The Vineland Motor Skills standard score and ADOS
Calibrated Severity score were not included in the regression
models because of the small sample size for these measures.
Autism Spectrum Disorder and Epilepsy
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Results
Sample Characteristics
The total sample size from all four studies combined was 5,815
participants with ASD, of whom 289 had co-occurring epilepsy.
The majority of total participants were male, ranging from 80.3%
male in AGRE to 86.4% male in SSC, and the majority were
between the ages of 4 and 12 years (Table 2). Most participants
were White, ranging from 66.9% White in the NSCH to 85.9%
White in the AC. Among genetic collaborative study total
participants for whom IQ data were available, 33.3% of AGRE,
28.8% of SSC, and 15.3% of AC participants had intellectual
disability (ID).
Occurrence of Epilepsy
The distribution of epilepsy in the AGRE, SSC, and AC studies
was 5.3% (n= 120), 2.9% (n= 51), and 6.7% (n= 30), respectively
with a combined frequency of 4.5% (n= 201) (Table 3). In the
population-based sample, the NSCH, the prevalence of epilepsy
was 12.5% (n= 88).
Clinical Characteristics of Individuals with Asd and
Epilepsy
Findings comparing individuals with ASD with and without
epilepsy are presented. Individual-level data from the genetic
collaborative samples were combined. Results from each of the
genetic collaborative samples can be found in Tables S1–S9 in
Supporting Information S1. As shown in Table 4 and Figure 1,
epilepsy was more prevalent in older children. Among children
aged 13 or older, 10.3% had epilepsy in the combined genetic
collaborative sample and 26.2% had epilepsy in the NSCH.
Epilepsy was more prevalent in females in the combined genetic
collaborative sample; 7% of females had epilepsy as compared to
3.9% of males (p,.001). In all of the genetic collaborative samples
the prevalence of epilepsy was greater in females, but this
difference was only statistically significant in the AGRE study
(Table S2 in Supporting Information S1). In the NSCH, there
were no gender differences in epilepsy prevalence. We also found
that among both males and females epilepsy rates increased
significantly with age.
Table 5 presents comparisons of clinical characteristics in
children with ASD with and without epilepsy from the combined
genetic collaborative sample. Children with a history of develop-
Table 2. Demographic Characteristics of Individuals with Autism Spectrum Disorder by Study Sample.
AGRE SSC AC NSCH
(n=2524) (n =1891) (n=479) (n =921)
Characteristic No. (%) Characteristic No.b (Wt. %)
Gender Gender
Male 2026 (80.3) 1633 (86.4) 388 (81.0) Male 753 (81.0)
Female 498 (19.7) 258 (13.6) 91 (19.0) Female 168 (19.0)
Age (years) Age (years)
Under 4 295 (11.7) 0 (0.0) 40 (8.4) 2–3 46 (3.1)
4–6 861 (34.1) 682 (36.1) 171 (35.7) 4–7 253 (27.4)
7–9 693 (27.5) 548 (29.0) 117 (24.4) 8–11 236 (33.4)
10–12 338 (13.4) 368 (19.5) 72 (15.0) 12–14 200 (22.2)
13–18 264 (10.5) 293 (15.5) 73 (15.2) 15–17 186 (14.0)
Over 18 73 (2.9) 0 (0.0) 6 (1.3) Over 18 N/A
Race Race
White 1781 (70.6) 1492 (78.9) 401 (85.9) White, Non-Hispanic 664 (66.9)
African-American 49 (1.9) 69 (3.6) 10 (2.1) Black, Non-Hispanic 57 (8.3)
Asian 62 (2.5) 70 (3.7) 11 (2.4) Hispanic 94 (19.1)
More Than One Race 170 (6.7) 157 (8.3) 30 (6.4) Other, Non-Hispanic 86 (5.6)
Other 12 (0.5) 83 (4.4) 2 (0.4) –
Not Specified 450 (17.8) 20 (1.1) 13 (2.8) –
Type of ASDa
Autism 2524 (100.0) 1700 (89.9) 428 (89.4) N/A
ASD N/A 191 (10.1) 51 (10.7) N/A
Intellectual Disability (ID)
Non- ID (IQ.70) 344 (66.7) 1345 (71.2) 238 (84.7) N/A
ID (IQ#70) 172 (33.3) 545 (28.8) 43 (15.3) N/A
Abbreviations: ASD, Autism Spectrum Disorder; AGRE, the Autism Genetic Resource Exchange; SSC, the Simons Simplex Collection; AC, the Autism Consortium; NSCH,
the 2007 National Survey of Children’s Health; Wt. %, weighted percentage; N/A: not applicable or data not unavailable.
aDiagnosis based on the Autism Diagnostic Interview, Revised (ADI-R) cut-off scores for autism and ASD (Risi et al. 2006).
bUnweighted number of children.
Values may not add up to total due to missing data.
doi:10.1371/journal.pone.0067797.t002
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mental regression were significantly more likely to have epilepsy
(6.7% of children with definite loss of language or skills had
epilepsy, as compared to 3.6% without loss, p,.001). With regard
to language, epilepsy was more prevalent in children with fewer
than 5 words and children with epilepsy had a significantly lower
mean PPVT score (67.8 vs. 85.9, p,.001). Epilepsy was associated
with significantly lower cognitive ability, as evidenced by a lower
mean IQ score in the epilepsy group (66.2 vs. 84.9, p,.001) and a
greater prevalence of epilepsy in children with ID (6.2% vs. 1.9%,
p,.001). Individuals with epilepsy also had poorer adaptive
functioning, as evidenced by significantly lower mean Adaptive
Behavior Composite score and Motor Skills standard score.
Children with epilepsy also had a significantly higher mean ADOS
Calibrated Severity score (7.4 vs. 7.1, p = 0.04), indicating more
severe ASD symptoms.
Table 6 presents logistic regression analyses modeling the odds
of epilepsy by demographic and clinical characteristics for
participants from the genetic collaborative samples. In the
unadjusted models (model 1), all of the characteristics were
significantly associated with epilepsy. In the models adjusted for
IQ (model 2), age was the only variable that remained associated
with epilepsy. In the multivariate model that adjusted for all of the
variables (model 3), age and full scale IQ score were the only
variables that significantly increased risk of epilepsy. Controlling
for all other variables in the model, individuals age 10 or older had
2.35 times the odds of being diagnosed with epilepsy (p,.001) and
for a one standard deviation increase in full scale IQ, the odds of
having epilepsy decreased by 47% (p,.001).
Discussion
This is among the largest studies to date of children with ASD
and co-occurring epilepsy. Our sample includes 5,815 participants
with ASD, 289 of whom had co-morbid epilepsy. Using statistical
modeling in this well-powered sample of patients we have made
several important observations about a contemporary group of
individuals with ASD and epilepsy. We identified several correlates
of epilepsy in children with ASD including older age, lower
cognitive and adaptive functioning, poorer language skills, a
history of developmental regression, and more severe ASD
symptoms. Through multivariate logistic regression we found that
only age and cognitive ability were independent predictors of
epilepsy.
The average prevalence of epilepsy among children aged 2 to 17
years in our population-based sample, the NSCH, was 12.5%.
Table 3. Distribution of Epilepsy among Individuals with Autism Spectrum Disorder by Study Sample.
Distribution of Epilepsy Prevalence of Epilepsy
AGRE SSC AC Combineda NSCH
(n=2273) (n=1786) (n =450) (n =4509) (n=918)
No. (%) No.b (Wt. %) (Wt. 95% CI)
Never Diagnosed with
Epilepsy
2153 (94.7) 1735 (97.1) 420 (93.3) 4308 (95.5) 830 (87.5)
Diagnosed with Epilepsy 120 (5.3) 51 (2.9) 30 (6.7) 201 (4.5) 88 (12.5) (10.4–14.7)
Abbreviations: AGRE, the Autism Genetic Resource Exchange; SSC, the Simons Simplex Collection; AC, the Autism Consortium; NSCH, the 2007 National Survey of
Children’s Health; Wt. %, weighted percentage; CI, confidence interval.
aGenetic Collaborative Samples (AGRE, SSC, and AC) combined.
bUnweighted number of children.
doi:10.1371/journal.pone.0067797.t003
Figure 1. Prevalence of Epilepsy by Age among Individuals with Autism Spectrum Disorder, All Studies. The percentage of children
with epilepsy by age group by study sample. The prevalence is higher in older children than younger children. Abbreviations: AGRE, the Autism
Genetic Resource Exchange; SSC, the Simons Simplex Collection; AC, the Autism Consortium; NSCH, 2007 the National Survey of Children’s Health.
doi:10.1371/journal.pone.0067797.g001
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This estimate is comparable to a recent report of a 15.5% rate of
epilepsy in another population-based sample of children with ASD
[42]. While the prevalence was 10% or lower in children under 13
years of age, by adolescence it reached 26.2%. Therefore, the best
estimate of the cumulative prevalence of epilepsy in ASD through
17 years of age is 26%. Our study replicates findings from prior
studies that have followed children with ASD into adolescence/
early adulthood and reported epilepsy prevalence rates from 22%
to 38% [14,15,21].
Population-based samples like the NSCH can provide accurate
estimates of the prevalence of epilepsy in the general population of
children with ASD by random sampling, which reduces sampling
bias and improves generalizability. However, these samples often
have smaller numbers of ASD cases and lack detailed phenotypic
information on study participants. In contrast, samples from
genetic collaboratives are less likely to be representative of the
greater ASD population due to specific inclusion and exclusion
criteria; however, these datasets are often large, include carefully
confirmed cases of ASD, and provide rich phenotypic information
collected with modern assessment tools. In the present study, we
make use of both a population-based sample and several genetic
collaborative samples allowing for an estimate of the prevalence of
epilepsy in ASD and an examination of important clinical
correlates of ASD and epilepsy. The average prevalence of
epilepsy found in the combined genetic collaborative sample of
4.5% and the cumulative estimate of 10.3% in children aged 13
and older was considerably lower than the prevalence in the
NSCH. This likely reflects the specific inclusion and exclusion
criteria of these samples, in particular, the tendency to recruit
children with higher-functioning ASD and to exclude children
with certain disorders and other conditions (i.e. some known
genetic syndromes) associated with epilepsy.
Additional strengths of our study are the large sample size and
detailed and standardized assessments of clinical correlates using
modern, reliable measures. The large sample size allowed us to use
regression modeling to examine the association between epilepsy
and various characteristics in a multivariate model. Because of
their small sample size, most prior studies have been unable to
control for confounders in the examination of risk factors for
epilepsy in ASD. In particular, there has been a need for an
examination of gender and epilepsy controlling for confounding by
cognitive ability [20].
As reported in previous studies [14,15,20,21], individuals with
epilepsy in our study had lower cognitive ability and were more
likely to have ID. Over half of children with epilepsy in the genetic
collaborative samples had ID and the mean IQ score for
individuals with ASD and co-morbid epilepsy was 66.2. Although
our findings with regard to IQ and epilepsy replicate those
reported in prior studies, our results are important given that the
IQ distribution of children with ASD has shifted considerably in
the last few years, as many more children with ASD without ID
are being identified [43]. The relationship between ASD, epilepsy
Table 4. Epilepsy Diagnosis by Gender and Age among Individuals with Autism Spectrum Disorder.
Combined Genetic Collaborative Samplea NSCH
(n=4509) (n =921)
Never Diagnosed
with Epilepsy
Diagnosed with
Epilepsy
Never Diagnosed
with Epilepsy Diagnosed with Epilepsy
No. (%) p-value No.b (Wt. %) (Wt. 95% CI) p-value
Age (years) ,.001 0.009
6 or under 1824 (97.8) 41 (2.2) 209 (94.6) 15 (5.4) (2.4–8.4)
7–9 1218 (96.2) 48 (3.8) 179 (92.9) 18 (7.1) (3.5–10.7)
10–12 682 (93.8) 45 (6.2) 172 (89.6) 17 (10.4) (6.0–14.8)
13 or older 574 (89.6) 67 (10.5) 270 (73.8) 38 (26.2) (21.2–31.1)
Gender ,.001 0.81
Male 3586 (96.1) 147 (3.9) 688 (87.3) 62 (12.7) (10.3–15.1)
Female 719 (93.0) 54 (7.0) 142 (88.5) 26 (11.5) (6.7–16.4)
Gender by Age
Male ,.001 ,.001
6 or under 1496 (98.1) 29 (1.9) 175 (95.7) 10 (4.3)
7–9 1020 (96.4) 38 (3.6) 148 (91.2) 14 (8.8)
10–12 581 (95.1) 30 (4.9) 144 (89.7) 11 (10.3)
13 or older 484 (90.6) 50 (9.4) 221 (70.8) 27 (29.2)
Female ,.001 ,.001
6 or under 328 (96.5) 12 (3.5) 34 (87.8) 5 (12.2)
7–9 198 (95.2) 10 (4.8) 31 (98.8) 4 (1.2)
10–12 101 (87.1) 15 (12.9) 28 (88.6) 6 (11.4)
13 or older 90 (84.1) 17 (15.9) 49 (81.2) 11 (18.8)
Abbreviations: NSCH, 2007 National Survey of Children’s Health; Wt. %, weighted percentage; CI, confidence interval.
aGenetic Collaborative Samples (AGRE, SSC, and AC) combined.
bUnweighted number of children.
doi:10.1371/journal.pone.0067797.t004
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and IQ is complex, and some investigators believe that the
association between autism and epilepsy is primarily driven by the
presence of ID [44]. van Eeghen et al. [45] found a strong inverse
association between autistic traits and IQ in persons with epilepsy.
They concluded that autistic features appear to be part of the
neurocognitive construct of disorders like epilepsy. They also
found associations between autistic traits and epilepsy in patients
with Tuberous Sclerosis. In addition to IQ, the present study
examined other related measures such as adaptive functioning and
language skills, which have not been extensively studied.
Our findings with regard to gender were mixed. Females were
significantly more likely to have epilepsy in the combined genetic
collaborative sample, but males were more likely to have epilepsy
in the NSCH (although this difference was not statistically
significant). We also found variation in the association between
gender and epilepsy in the individual genetic collaborative
samples; while all of the samples showed a higher proportion of
females with epilepsy, this difference was only statistically
significant in the multiplex sample (AGRE). Tuchman [46] found
that female gender was not a risk factor for epilepsy after
controlling for ID and motor deficit. In contrast, Bolton [15] found
that female gender was significantly associated with epilepsy even
after adjusting for verbal ability and non-verbal IQ. In the present
study, female gender was associated with epilepsy among subjects
of the genetic collaborative samples only in the unadjusted logistic
regression model; gender was not an independent risk factor for
epilepsy after adjusting for IQ. The association between gender
and epilepsy is theorized to be due to a greater proportion of
females with ASD having low cognitive ability [47], as low IQ is
associated with epilepsy. This is supported by our finding that
female gender was not associated with increased risk of epilepsy
after controlling for IQ. However, this theory cannot be confirmed
based on our statistical observations alone. It is also possible that
there is a biological mechanism by which females with ASD are at
Table 5. Epilepsy Diagnosis by Clinical Characteristics among Individuals with Autism Spectrum Disorder, Genetic Collaborative
Samples.
Combined Genetic Collaborative Samplea
(n=4509)
Never Diagnosed with Epilepsy Diagnosed with Epilepsy
No. (%) p-value
Regression
Any Regression ,.001
No Definite Loss 3095 (96.4) 114 (3.6)
Definite Loss 1210 (93.3) 87 (6.7)
Loss of Any Language .001
No 2911 (96.8) 96 (3.2)
Yes 615 (94.2) 38 (5.8)
Loss of Skills ,.001
No Consistent Loss 2680 (97.0) 82 (3.0)
Probable Loss 127 (92.0) 11 (8.0)
Definite Loss 712 (94.7) 40 (5.3)
Language ,.001
Overall Level of Language
Meaningful Use of Phrases 3366 (96.5) 123 (3.5)
Fewer than 5 Words 463 (92.2) 39 (7.8)
PPVT Score 3251 (85.9, 27.9) 110 (67.8, 31.3) ,.001
Cognitive Ability
Intellectual Disability (ID) ,.001
Non- ID (IQ .70) 1797 (98.1) 34 (1.9)
ID (IQ ,70) 653 (93.8) 43 (6.2)
No. (Mean, SD)
Full Scale IQ Score 2450 (84.9, 25.7) 77 (66.2, 26.8) ,.001
Adaptive Functioning
Adaptive Behavior Composite Score 3531 (68.1, 17.5) 151 (55.3, 20.7) ,.001
Motor Skills Standard Score 2171 (82.3, 18.4) 94 (73.0, 21.5) ,.001
ASD Severity
ADOS Calibrated Severity Score 3153 (7.1, 1.9) 119 (7.4, 1.8) 0.04
Abbreviations: SD, standard deviation, PPVT, Peabody Picture Vocabulary Test; ADOS, Autism Diagnostic Observation Schedule.
aGenetic Collaborative Samples (AGRE, SSC, and AC) combined.
Values may not add up to total due to missing data.
doi:10.1371/journal.pone.0067797.t005
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increased risk for both lower IQ and epilepsy. Further research is
needed to better understand the association between gender and
epilepsy in ASD and to determine if the association differs in
multiplex versus simplex families.
Epilepsy onset in persons without autism has been shown to be
highest in the first year of life [48,49] and generally shows a bi-
modal curve with higher rates in early and later life [50]. In
persons with ASD, two peaks of seizure onset have been reported,
one in early childhood [9] and one in adolescence and continuing
through adulthood [51]. This pattern may be unique to individuals
with ASD [5]. We found a higher prevalence of epilepsy in
children with ASD of older age, which is expected given that older
children have had a longer amount of time to develop epilepsy.
The pattern was evident in both males and females with ASD
showing that it is independent of gender. This finding is in line
with other studies that report the highest epilepsy rates in samples
that include adolescents and adults. It is also consistent with studies
showing a peak in epilepsy onset in adolescence [52]. A limitation
of our study is that the sample included a large number of young
participants, and given that this is a cross-sectional study, we
cannot be certain that some of the participants will not develop
epilepsy at a later time.
Additional limitations should be considered when interpreting
the results of this study. First, we relied exclusively on parent
report for the diagnosis of epilepsy, which may have resulted in
misclassification. For a subset of participants from the genetic
collaborative samples (n = 2,525) we were able to cross-validate
parent report of epilepsy diagnosis on the ADI-R with assessment
of non-febrile seizures based on a medical history interview or
questionnaire. We found that children reported by their parent to
have epilepsy on the ADI-R were highly likely (95%) to also have a
history of non-febrile seizures based on medical history (Table S10
in Supporting Information S1). This provides support for the
reliability of the parent-report epilepsy measure. Furthermore,
previous studies have used the ADI-R to identify cases of epilepsy
in children with ASD [15,53]. In addition, we relied on parent-
report of ASD diagnosis in the NSCH. However, a number of
studies have utilized maternally-reported diagnosis of ASD and
other child health conditions and shown the reliability of these
reports [54,55]. In addition, parent report of medical conditions in
the NSCH were consistent with those expected by clinical
assessment [56] and the NSCH has been used to estimate the
prevalence of ASD in the United States [57].
Another limitation is that the genetic collaborative samples were
ascertained based on the nature of the pedigrees sought, specific
inclusion and exclusion criteria, and the ability of the affected
participants to complete the extensive phenotyping batteries. A
smaller percentage of participants in the genetic collaborative
samples had cognitive abilities in the ID range, as compared to the
rate in the general ASD population, recently reported to be 38%
[43]. This may in part explain the lower occurrence of epilepsy
found in these samples as compared to the NSCH. We did not use
the genetic collaborative samples for estimates of epilepsy
prevalence given that they are not population-based samples.
Instead, we used these samples to examine clinical characteristics
that are less likely to be affected by this sampling bias.
There was also some heterogeneity across the genetic collab-
orative samples in the occurrence and clinical correlates of
epilepsy due to differences between the samples. We combined
data from the genetic collaborative samples in our main analyses,
Table 6. Logistic Regression Modeling the Odds of an Epilepsy Diagnosis by Demographic and Clinical Characteristics, Combined
Genetic Collaborative Samplea.
Model 1: Unadjusted Model 2: Adjusted for FSIQ Model 3: Fully Adjusted
Characteristic OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age
9 years and younger 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
10 years and older 3.05 (2.29–4.06) ,.001 2.40 (1.51–3.82) ,.001 2.35 (1.42–3.88) ,.001
Gender
Male 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
Female 1.86 (1.35–2.56) ,.001 1.43 (0.82–2.49) 0.21 1.36 (0.77–2.43) 0.29
Cognitive Ability
Full Scale IQ Score 0.51 (0.4 1–0.63) ,.001 0.51 (0.41–0.63) ,.001 0.53 (0.39–0.73) ,.001
Adaptive Functioning
Adaptive Behavior Composite Score 0.52 (0.45–0.61) ,.001 0.80 (0.58–1.10) 0.17 0.98 (0.70–1.37) 0.89
Language
Meaningful Use of Single Words, Two-
Word Phrases, or Three-Word Phrases
1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
Fewer than 5 Words 2.00 (1.39–2.87) ,.001 0.75 (0.27–2.05) 0.57 0.75 (0.27–2.13) 0.59
Developmental Regression
No Loss of Language or Skills 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
Loss of any Language or Skills 1.93 (1.45–2.57) ,.001 1.05 (0.64–1.72) 0.86 1.14 (0.69–1.89) 0.60
Abbreviations: OR, odds ratio; CI, confidence interval; FSIQ, full scale IQ score.
aGenetic Collaborative Samples (AGRE, SSC, and AC) combined.
Model 1: Individual models for each variable.
Model 2: Individual models for each variable, adjusted for full scale IQ score only.
Model 3: Single model adjusted for all variables.
Odds ratios for full scale IQ score and adaptive behavior composite score represent the odds of epilepsy for a one standard deviation increase.
doi:10.1371/journal.pone.0067797.t006
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which may not reflect the findings from the individual samples (see
Tables S1–S9 in Supporting Information S1 for results from the
individual studies). However, these differences were minor and in
general, the results were similar across samples, suggesting that
combining individual level data from each of the studies was
appropriate.
An additional caveat to our study is missing data. In particular,
IQ data were available for only a subset of participants. Genetic
study participants for whom we had IQ data had somewhat higher
IQ than would be expected in a representative sample of children
with ASD (as mentioned above). The subjects used in the
multivariate regression models were more likely to be from the
SSC sample due to missing IQ data among AC and AGRE
participants. As such, the findings may be more applicable to
children with ASD from simplex families who meet the specific
inclusion criteria of the SSC study. We conducted sensitivity
analyses to determine if the results would differ if more
participants from the AC and AGRE samples were included in
the regression model. When we ran the analyses using PPVT score
as a measure cognitive ability (which was available for the majority
of genetic collaborative participants), instead of IQ score, the
results were the same. Furthermore, when fully adjusted regression
models were run separately in each of the genetic collaborative
study samples the results were similar to the results from the
combined sample (Table S9 in Supporting Information S1). The
effect sizes (odds ratios) from the individual studies were similar to
the combined sample; however in the AGRE sample gender was a
significant predictor of epilepsy and IQ was a non-significant
predictor. This is likely to be explained by the small number of
AGRE participants with IQ data.
Individuals with ASD and epilepsy are an important subgroup
of patients who require specialized medical care and may be of
etiological significance to understanding the neurobiology of ASD.
It has been suggested that the most common reason for the co-
occurrence of ASD and epilepsy is that the same brain pathology
causes both disorders [58]. Turk et al. [18] found that children
with ASD and epilepsy were more likely to receive a later ASD
diagnosis and have additional medical disorders, motor difficulties,
developmental delays, and challenging behaviors, compared to
children with ASD only. Perhaps most striking, persons with ASD
and epilepsy have higher mortality rates [21,59]. The ASD-
epilepsy subgroup may also be helpful to genetic research into
ASD etiology. Duplications of the 15q11–13 locus or 15q13 copy
number variants are frequently associated with ASD and epilepsy,
and several key candidate genes are located in these intervals [3].
Recent sequencing studies in autism have identified de novo variants
in a variety of epilepsy-related genes [60,61,62,63].
Conclusions
Our findings suggest that epilepsy is a common co-morbid
condition in individuals with ASD, occurring in approximately
12% of children with ASD and reaching 26% by adolescence.
In a large, contemporary sample of children with ASD, we
identified several risk factors for epilepsy including older age,
low IQ and adaptive functioning, poor language skills, a history
of developmental regression, and more severe ASD symptoms.
Through statistical modeling we demonstrated that the most-
widely reported factors associated with epilepsy are not
predictive after adjusting for IQ. Low IQ is the best clinical
predictor of epilepsy in children with ASD. These findings can
help guide prognosis and alert clinicians to patients who are at
increased risk for epilepsy.
Supporting Information
Supporting Information S1 Supporting Tables. Table S1
Epilepsy Diagnosis by Age among Individuals with Autism
Spectrum Disorder, Genetic Collaborative Samples. The preva-
lence of epilepsy was significantly higher in older children in all of
the genetic collaborative samples. Table S2 Epilepsy Diagnosis by
Gender among Individuals with Autism Spectrum Disorder,
Genetic Collaborative Samples. The prevalence of epilepsy was
higher in females with ASD in all of the genetic collaborative
samples, but this difference only reached statistical significance in
the AGRE sample. Table S3 Epilepsy Diagnosis by History of
Developmental Regression among Individuals with Autism
Spectrum Disorder, Genetic Collaborative Samples. The preva-
lence of epilepsy was higher in individuals with a history of
developmental regression in all of the genetic collaborative
samples. Table S4 Epilepsy Diagnosis by Language among
Individuals with Autism Spectrum Disorder, Genetic Collabora-
tive Samples. The prevalence of epilepsy was significantly higher
in individuals with fewer than 5 words in all of the genetic
collaborative samples. Table S5 Epilepsy Diagnosis by Cognitive
Ability among Individuals with Autism Spectrum Disorder,
Genetic Collaborative Samples. Individuals with epilepsy had
significantly lower cognitive ability in all of the genetic
collaborative samples. Table S6 Epilepsy Diagnosis by Intellec-
tual Disability among Individuals with Autism Spectrum Disorder,
Genetic Collaborative Samples. The prevalence of epilepsy was
higher in individuals with intellectual disability in all of the genetic
collaborative samples. Table S7 Epilepsy Diagnosis by Adaptive
Functioning among Individuals with Autism Spectrum Disorder,
Genetic Collaborative Samples. Individuals with epilepsy had
significantly lower adaptive functioning in all of the genetic
collaborative samples. Table S8 Epilepsy Diagnosis by Autism
Severity among Individuals with Autism Spectrum Disorder,
Genetic Collaborative Samples. Individuals with epilepsy had
higher mean ADOS Calibrated Severity scores in all of the genetic
collaborative samples. Table S9 Logistic Regression Modeling the
Odds of an Epilepsy Diagnosis by Demographic and Clinical
Characteristics, Individual Genetic Collaborative Samples. Logis-
tic regression model findings were similar in participants of the
individual genetic collaborative samples to the results from the
combined sample. Table S10 Cross-Validation of Parent Report
Epilepsy Diagnosis on the ADI-R with Report of Non-Febrile
Seizures based on Medical History, Subset of Genetic Collabo-
rative Study Participants (n = 2,525). There was good agreement
between parent report of epilepsy diagnosis on the ADI-R and
medical history.
(DOCX)
Acknowledgments
We are grateful for the input of David Mandelbaum MD, PhD and John
N. Gaitanis MD. We gratefully acknowledge the resources provided by the
Autism Genetic Resource Exchange (AGRE) Consortium and the
participating AGRE families. The AGRE is a program of Autism Speaks
and is supported, in part, by grant 1U24MH081810 from the National
Institute of Mental Health to Clara M. Lajonchere (PI). We are grateful to
all of the families at the participating Simons Simplex Collection (SSC)
sites, as well as the principal investigators (A. Beaudet, R. Bernier, J.
Constantino, E. Cook, E. Fombonne, D. Geschwind, D. Grice, A. Klin, D.
Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley,
B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C.
Walsh, E. Wijsman). We appreciate obtaining access to phenotypic data on
SSC Base. We thank the families who agreed to participate in the Autism
Consortium (AC). The AC Clinical Genetics Team is a collaborative effort
of Boston Medical Center, Children’s Hospital Boston, Cambridge Health
Autism Spectrum Disorder and Epilepsy
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e67797
Alliance, the Massachusetts General Hospital LADDERS (Learning and
Developmental Disabilities Evaluation & Rehabilitation Services) Program,
and Tufts Medical Center.
Author Contributions
Conceived and designed the experiments: EMM EWV EWT RMJ SJS.
Performed the experiments: EWV. Analyzed the data: EMM EWV EWT
MFP. Wrote the paper: EMM EWV. Managed data: MFP. Provided
expert advice regarding neuropsychological test data: RM.
References
1. Commission on Epidemiology and Prognosis ILAE (1993) Guidelines for
epidemiologic studies on epilepsy. Epilepsia 34: 592–596.
2. Tuchman R, Rapin I (2002) Epilepsy in autism. Lancet Neurology 1: 352–358.
3. Canitano R (2007) Epilepsy in Autism Spectrum Disorders. Eur Child Adolesc
Psychiatry 16: 61–66.
4. Rapin I, Katzman R (1998) Neurobiology of autism. Ann Neurol 43: 7–14.
5. Tuchman R, Cuccaro M, Alessandri M (2010) Autism and epilepsy: Historical
perspective. Brain & Development 32: 709–718.
6. Maski KP, Jeste SS, Spence SJ (2011) Common neurological co-morbidities in
autism spectrum disorders. Curr Opin Pediatr 23: 609–615.
7. Forsgren L, Beghi E, Oun A, Sillanpa¨a¨ M (2005) The epidemiology of epilepsy
in Europe - a systematic review. Eur J Neurol 12: 245–253.
8. Spence SJ, Schneider MT (2009) The role of epilepsy and epileptiform EEGs in
autism spectrum disorders. Pediatric Research 65: 599–606.
9. Volkmar FR, Nelson DS (1990) Seizure disorders in autism. J Am Acad Child
Adolesc Psychiatry 29: 127–129.
10. Mouridsen SE, Rich B, Isager T (1999) Epilepsy in disintegrative psychosis and
infantile autism: a long-term validation study. Developmental Medicine & Child
Neurology 41: 110–114.
11. Olsson I, Steffenburg S, Gillberg C (1988) Epilepsy in autism and autisticlike
conditions. A population-based study. Arch Neurol 45: 666–668.
12. Kielinen M, Rantala H, Timonen E, Linna SL, Moilanen I (2004) Associated
medical disorders and disabilities in children with autistic disorder: a population-
based study. Autism 8: 49–60.
13. Canitano R, Luchetti A, Zappella M (2005) Epilepsy, electroencephalographic
abnormalities, and regression in children with autism. J Child Neurol 20: 27–31.
14. Hara H (2007) Autism and epilepsy: a retrospective follow-up study. Brain Dev
29: 486–490.
15. Bolton PF, Carcani-Rathwell I, Hutton J, Goode S, Howlin P, et al. (2011)
Epilepsy in autism: features and correlates. The British Journal of Psychiatry
198: 289–294.
16. Wong V (1993) Epilepsy in children with autistic spectrum disorder. J Child
Neurol 8: 316–322.
17. Pavone P, Incorpora G, Fiumara A, Parano E, Trifiletti RR, et al. (2004)
Epilepsy is not a prominent feature of primary autism. Neuropediatrics 35: 207–
210.
18. Turk J (2009) Autism spectrum disorder in children with and without epilepsy:
impact on social functioning and communication. Acta Pædiatrica 98: 675–681.
19. Rossi PG, Parmeggiani A, Bach V, Santucci M, Visconti P (1995) EEG features
and epilepsy in patients with autism. Brain Dev 17: 169–174.
20. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, et al. (2008)
Epilepsy in autism is associated with intellectual disability and gender: evidence
from a meta-analysis. Biol Psychiatry 64: 577–582.
21. Danielsson S, Gillberg IC, Billstedt E, Gillberg C, Olsson I (2005) Epilepsy in
young adults with autism: A prospective population-based follow-up study of 120
individuals diagnosed in childhood. Epilepsia 46: 918–923.
22. Hrdlicka M, Komarek V, Propper L, Kulisek R, Zumrova A, et al. (2004) Not
EEG abnormalities but epilepsy is associated with autistic regression and mental
functioning in childhood autism. Eur Child Adolesc Psychiatry 13: 209–213.
23. Hishinuma ES, Miyamoto RH, Nishimura ST, Nahulu LB, Andrade NN, et al.
(2000) Psychometric properties of the state-trait anxiety inventory for Asian/
Pacific-islander adolescents. Assessment 7: 17–36.
24. Blumberg SJ, Foster EB, Frasier AM, Satorius J, Skalland BJ, et al. (2009) Design
and operation of the National Survey of Children’s Health, 2007. Vital Health
Stat 1.
25. Geschwind DH, Sowinski J, Lord C, Iversen P, Shestack J, et al (2001) The
autism genetic resource exchange: A resource for the study of autism and related
neuropsychiatric conditions. Am J Hum Genet 69: 463–466.
26. Lajonchere CM (2010) Changing the Landscape of Autism Research: The
Autism Genetic Resource Exchange. Neuron 68: 187–191.
27. Simons (2010) SFARI Base/SSC Researcher Welcome Packet.
28. Fischbach GD, Lord C (2010) The Simons Simplex Collection: A Resource for
Identification of Autism Genetic Risk Factors. Neuron 68: 192–195.
29. Rutter M, Le Couteur A, Lord C (2003) ADI-R : Autism Diagnostic Interview–
Revised : manual. Los Angeles, CA: Western Psychological Services. v 60, [10]
pp.
30. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, et al. (2000) The
autism diagnostic observation schedule-generic: a standard measure of social and
communication deficits associated with the spectrum of autism. J Autism Dev
Disord 30: 205–223.
31. APA (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR.
Washington, DC: American Psychiatric Association. xxxvii, 943 pp.
32. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, et al. (2006) Combining
information from multiple sources in the diagnosis of autism spectrum disorders.
J Am Acad Child Adolesc Psychiatry 45: 1094–1103.
33. Roid GH (2003a) Stanford-Binet Intelligence Scales, Fifth Edition. Itasca, IL:
Riverside Publishing.
34. Elliott CD (2007a) Differential Ability Scales–Second edition (DAS-II). San
Antonio, TX: Harcourt.
35. Mullen EM, American Guidance Service (1995) Mullen Scales of Early
Learning. Circle Pines, MN: AGS.
36. Wechsler D (1999) Wechsler abbreviated scale of intelligence: WASI. San
Antonio: Psychological Corporation Harcourt Brace.
37. Wechsler D (1967) Manual for the Wechsler Preschool and Primary Scale of
Intelligence. San Antonio, TX: The Psychological Corporation.
38. Sparrow SS, Balla DA, Cicchetti DV (2005) Vineland adaptive behavior scales
II. Circle Pines, MN: American Guidance Service.
39. Dunn LM, Dunn LM (1997) Peabody Picture Vocabulary Test-Fourth Edition.
Circle Pines, MN: AGS.
40. Gotham K, Pickles A, Lord C (2009) Standardizing ADOS scores for a measure
of severity in autism spectrum disorders. J Autism Dev Disord 39: 693–705.
41. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, et al. (2000) The Autism
Diagnostic Observation Schedule-Generic: A Standard Measure of Social and
Communication Deficits Associated with the Spectrum of Autism. Journal of
Autism and Developmental Disorders 30: 205–223.
42. Levy SE, Giarelli E, Lee LC, Schieve LA, Kirby RS, et al. (2010) Autism
spectrum disorder and co-occurring developmental, psychiatric, and medical
conditions among children in multiple populations of the United States. J Dev
Behav Pediatr 31: 267–275.
43. Baio J (2012) Prevalence of autism spectrum disorders - autism and
developmental disabilities monitoring network, 14 sites, United States, 2008.
MMWR Surveill Summ 61: 1–19.
44. Berg AT, Plioplys S (2012) Epilepsy and autism: is there a special relationship?
Epilepsy Behav 23: 193–198.
45. van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, et
al. (2013) Understanding relationships between autism, intelligence, and
epilepsy: a cross-disorder approach. Dev Med Child Neurol 55: 146–153.
46. Tuchman R, Rapin I, Shinnar S (1991) Autistic and Dysphasic Children. II:
Epilepsy. Pediatrics 6: 1219–1225.
47. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, et al. (2007) The
epidemiology of autism spectrum disorders. Annu Rev Public Health 28: 235–
258.
48. Ellenberg JH, Hirtz DG, Nelson KB (1984) Age at onset of seizures in young
children. Ann Neurol 15: 127–134.
49. Hauser WA (1994) The prevalence and incidence of convulsive disorders in
children. Epilepsia 35 Suppl 2: S1–6.
50. Hauser WA, Annegers JF, Kurland LT (1993) Incidence of epilepsy and
unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 34: 453–
468.
51. Tuchman R, Cuccaro M (2011) Epilepsy and autism: neurodevelopmental
perspective. Curr Neurol Neurosci Rep 11: 428–434.
52. Deykin EY, MacMahon B (1979) The incidence of seizures among children with
autistic symptoms. Am J Psychiatry 136: 1310–1312.
53. Cuccaro ML, Tuchman RF, Hamilton KL, Wright HH, Abramson RK, et al.
(2011) Exploring the Relationship Between Autism Spectrum Disorder and
Epilepsy Using Latent Class Cluster Analysis. J Autism Dev Disord.
54. Faraone SV, Biederman J, Milberger S (1995) How reliable are maternal reports
of their children’s psychopathology? One-year recall of psychiatric diagnoses of
ADHD children. J Am Acad Child Adolesc Psychiatry 34: 1001–1008.
55. Schieve LA, Rice C, Boyle C, Visser SN, Blumberg SJ (2006) Mental health in
the United States: parental report of diagnosed autism in children aged 4–17
years–United States, 2003–2004. MMWRMorb Mortal Wkly Rep 55: 481–486.
56. U.S. Department of Health and Human Services MaCHB (2009) The Health
and Well-Being of Children: A Portrait of States and the Nation 2007. Rockville,
Maryland: U.S. Department of Health and Human Services.
57. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, et al. (2009)
Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among
Children in the US, 2007. Pediatrics 124: 1395–1403.
58. Deonna T, Roulet E (2006) Autistic spectrum disorder: evaluating a possible
contributing or causal role of epilepsy. Epilepsia 47 Suppl 2: 79–82.
59. Pickett J, Xiu E, Tuchman R, Dawson G, Lajonchere C (2011) Mortality in
individuals with autism, with and without epilepsy. J Child Neurol 26: 932–939.
60. Neale BM, Kou Y, Liu L, Ma’ayan A, Samocha KE, et al. (2012) Patterns and
rates of exonic de novo mutations in autism spectrum disorders. Nature.
Autism Spectrum Disorder and Epilepsy
PLOS ONE | www.plosone.org 10 July 2013 | Volume 8 | Issue 7 | e67797
61. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, et al. (2012)
De novo mutations revealed by whole-exome sequencing are strongly associated
with autism. Nature.
62. O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, et al. (2012) Sporadic
autism exomes reveal a highly interconnected protein network of de novo
mutations. Nature.
63. Veeramah KR, O’Brien JE, Meisler MH, Cheng X, Dib-Hajj SD, et al. (2012)
De Novo Pathogenic SCN8A Mutation Identified by Whole-Genome
Sequencing of a Family Quartet Affected by Infantile Epileptic Encephalopathy
and SUDEP. Am J Hum Genet 90: 502–510.
Autism Spectrum Disorder and Epilepsy
PLOS ONE | www.plosone.org 11 July 2013 | Volume 8 | Issue 7 | e67797
